2 soaring growth stocks I’d consider buying today

These two stocks have grown strongly in recent years and Harvey Jones expects further progress.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Drug developer Indivior (LSE: INDV) was set up in 1994 to pioneer treatments for opioid dependence and three years after floating now boasts a market cap of £2.9bn. However, it suffered a major blow at the end of August, its share price crashing 40% after the District Court of Delaware allowed the marketing of Dr Reddy’s, a rival, generic version of Indivior’s Suboxone film treatment for opioid addiction that generates 80% of its revenues.

Bitter pill

Indivior has since recovered and remains a great growth stock for shrewd investors. At 400p its share price is only 4% below its pre-crash level, as investors decided the damage may not be so severe after all. As well as the pill, the group also offers patient management, and is working on new projects and building relationships to hang onto its market share and diversify from its main product. All is not lost.

Today the company published its nine-month financial results and full-year guidance, with the share price up 0.65% in consequence. There are positives in there, with net revenue up 4% to $828m year-to-date, as strong US market growth offset generic competition. Operating profit jumped from $78m to $308m on higher net revenues and lower R&D and legal expenses, with adjusted operating profit up 6% to $333m. The company’s net cash now stands at $322m, up from $131 in full-year 2016.

News dependent

Indivior is appealing the Delaware ruling on its generic rival so investors must allow for the uncertainty surrounding the outcome. The other development to watch is its promising pipeline, following its successful NDA submission of RBP-7000 in schizophrenia and the endorsement of the FDA’s Psychopharmacologic Drugs Advisory and Drug Safety and Risk Management Advisory Committees for RBP-6000.This is the group’s “potentially transformational” product for the treatment of opioid use disorder.

Today’s forecast valuation of 11.4 times earnings reflects the uncertainty, with City analysts expecting earnings and revenue volatility going forward. The share price stands 95% higher than two years ago and it remains tempting, but only if you understand all the risks.

Keep informed

Business media giant Informa (LSE: INF) has also enjoyed a strong growth spurt, its share price up 85% over five years and 32% over two. Recent half-yearly results showed pre-tax profits rising 50% to £148.8m with revenues up 41.3% due to strong trading in its global exhibitions division. It is nice to see somebody making money from publishing, aside from Facebook.

Global exhibitions now make up 37.4% of the group’s total revenue after rising an impressive 77.7% to £342.8m. There was good news for income investors as well with the interim dividend increase 6.2% to 6.65p. The yield is still a relatively lowly 2.79% but the board is showing progression on this front. 

Solid growth

I have just been reading this £5.9bn FTSE 100 firm’s earnings per share (EPS) growth history and I have rarely seen one more consistent, with five consecutive years of low-single-digit growth. Markets are forecasting more action with 10% growth in 2017 and 7% in 2018.

The forecast yield is 3%, handily covered 2.3 times. Today you can buy Informa at a fair 14.8 times earnings, which suggests that this growth stock could be a bargain. It may not promise spectacular returns, but it looks extremely solid.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »